Since either upregulation of ATG16L2 expression or downregulation of ATG16L1 expression in human tumors should increase the competitive binding of ATG16L2 to ATG5, we calculated the ATG16L2:ATG16L1 mRNA expression ratio in normal and tumor samples from the TCGA mRNA datasets. The gene discussed is ATG16L2; the disease is neoplasm.